Livafin-O 100 Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. Disruption of ergosterol synthesis leads to increased membrane permeability and ultimately fungal cell death. Livafin-O 100 is commonly prescribed for conditions such as blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and other dermatophytic infections. It is effective against a wide range of pathogenic fungi including Candida species, Aspergillus species, and dermatophytes. The capsule formulation facilitates oral administration with good bioavailability when taken with food. Dosage and duration of therapy depend on the type and severity of infection and should be guided by clinical response and susceptibility testing. Caution is advised in patients with hepatic impairment, and periodic liver function monitoring is recommended during prolonged therapy. Livafin-O 100 should be used under medical supervision, considering potential drug interactions due to its influence on cytochrome P450 enzymes.